Aliskiren hemifumarate Good Manufacturer supply High Quality 173334-58-2
- Molecular Formula:2(C30H53N3O6).C4H4O4
- Molecular Weight:609.804
- Appearance/Colour:white powder
- Vapor Pressure:1.59E-23mmHg at 25°C
- Melting Point:72-75?C
- Boiling Point:748.4 °C at 760 mmHg
- Flash Point:406.4 °C
- PSA：366.86000
- LogP:9.88180
Aliskiren hemifumarate (173334-58-2) Usage
Aliskiren hemifumarate (Tekturna(R)) was the first renin inhibitor approved by FDA in March 2007, and genomic analysis validated that Pgx-based dosing guidelines are not required for this drug. The once-daily, oral, direct renin inhibitor received FDA approval for treatment of high blood pressure as mono therapy or in combination with other antihypertensive medications. Furthermore, aliskiren demonstrated increased efficacy when used in combination with other commonly used blood pressure-lowering medications. Novartis is conducting a large outcome trial program to evaluate the long-term effects of aliskiren and of direct renin inhibition in general.
How to get the best price on Aliskiren hemifumarate?
Zibo Hangyu Biotechnology Development Co., Ltd is a quality supplier and manufacturer of Aliskiren hemifumarate . You can buy high quality, low price Aliskiren hemifumarate 173334-58-2 here.
Zibo Hangyu Biotechnology Development Co., Ltd. is a comprehensive chemical enterprise focusing on fine chemical products and pharmaceutical intermediates, integrating research and development, production and sales. The company is equipped with advanced equipment quality inspection and research center. At the same time, the company has excellent talents with rich experience in process development and quality control. To provide customers with total solutions from raw material processing to chemical synthesis systems. The company has established a standardized and perfect quality standard system to provide stable and high quality production and service.
Milestones
- 2012yearThe company was founded, began to engage in the production and supply of chemical raw materials
- 2014yearExpand the scale of production, pharmaceutical raw materials production workshop was established
- 2016yearCooperated with domestic and foreign chemical platforms to promote self-produced and high-end pharmaceutical intermediates
- 2019yearIn recent years to participate in the international pharmaceutical raw materials exhibitions
- 2023yearBusiness continues to expand, Production and Sales teams continue to grow
- 2026yearPlans to set up foreign branches
